Last Updated: November 16, 2026

Tebipenem pivoxil hydrobromide - Generic Drug Details

« Back to Dashboard


What are the generic drug sources for tebipenem pivoxil hydrobromide and what is the scope of patent protection?

Tebipenem pivoxil hydrobromide is the generic ingredient in one branded drug marketed by Glaxosmithkline and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for tebipenem pivoxil hydrobromide
Generic Entry Date for tebipenem pivoxil hydrobromide*:
Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for tebipenem pivoxil hydrobromide

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Spero TherapeuticsPHASE1
GlaxoSmithKlinePHASE1
GlaxoSmithKlinePhase 3

See all tebipenem pivoxil hydrobromide clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for tebipenem pivoxil hydrobromide

US Patents and Regulatory Information for tebipenem pivoxil hydrobromide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline UTEBZI tebipenem pivoxil hydrobromide TABLET;ORAL 215960-001 Jun 17, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Glaxosmithkline UTEBZI tebipenem pivoxil hydrobromide TABLET;ORAL 215960-001 Jun 17, 2026 RX Yes Yes 10,889,587 ⤷  Start Trial Y Y ⤷  Start Trial
Glaxosmithkline UTEBZI tebipenem pivoxil hydrobromide TABLET;ORAL 215960-001 Jun 17, 2026 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Glaxosmithkline UTEBZI tebipenem pivoxil hydrobromide TABLET;ORAL 215960-001 Jun 17, 2026 RX Yes Yes 12,226,403 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Tebipenem Pivoxil Hydrobromide Market Dynamics and Financial Trajectory

Last updated: August 31, 2026

Tebipenem pivoxil hydrobromide is an investigational oral carbapenem developed for complicated urinary tract infections and acute pyelonephritis, including infections caused by extended-spectrum beta-lactamase-producing organisms. The product has no U.S. sales, no FDA approval, and no Orange Book-listed patents because its New Drug Application received a Complete Response Letter in 2022. Its commercial value depends on resolving manufacturing issues, securing a new regulatory pathway, and demonstrating that physicians will use an oral carbapenem without accelerating resistance.

The asset’s financial profile is therefore milestone-driven rather than revenue-driven. Spero Therapeutics licensed global rights from Meiji Seika Pharma and later entered a major development and commercialization agreement with GSK. The GSK relationship supplied near-term capital and validation but also created strategic risk because large pharmaceutical companies have become selective in anti-infective development.

What is tebipenem pivoxil hydrobromide?

Tebipenem pivoxil hydrobromide is the oral prodrug of tebipenem, a carbapenem antibiotic. After oral administration, tebipenem pivoxil is converted to active tebipenem.

Attribute Details
Active drug Tebipenem
Prodrug Tebipenem pivoxil
Salt form Hydrobromide
Drug class Oral carbapenem beta-lactam
Lead developer Spero Therapeutics
Original partner Meiji Seika Pharma
Target indications Complicated urinary tract infection and acute pyelonephritis
Primary commercial advantage Potential oral treatment for infections generally managed with intravenous carbapenems
U.S. status Not approved
FDA application NDA 215866
Regulatory outcome Complete Response Letter in November 2022
Current revenue status No commercial product revenue in the United States

Tebipenem pivoxil has been marketed in Japan as Orapenem for pediatric infections, but the U.S. development program targeted adults with complicated urinary tract infections and pyelonephritis.

What is the FDA regulatory status of tebipenem?

Tebipenem pivoxil hydrobromide is not FDA-approved in the United States. The FDA accepted Spero’s NDA for priority review and issued a Complete Response Letter on November 3, 2022.

The FDA’s action was primarily associated with deficiencies in the proposed manufacturing process and commercial product, rather than a public finding that the clinical efficacy dataset was inadequate. Spero stated that the agency did not identify concerns with the clinical efficacy or safety data supporting the application, but the CMC issues prevented approval.[1]

FDA regulatory timeline

Date Event
2016 Spero licensed tebipenem pivoxil hydrobromide from Meiji Seika Pharma
2018 FDA granted Qualified Infectious Disease Product designation
2019 FDA granted Fast Track designation
2021 Spero submitted the NDA for complicated urinary tract infections
2022 FDA accepted the NDA for priority review
November 2022 FDA issued a Complete Response Letter
2022-2024 Development and partnering strategy were reassessed
Future Approval requires resolution of CMC issues and a successful resubmission

The regulatory delay materially changes the financial model. Every year without approval postpones product revenue while preserving development, manufacturing, regulatory, and partnering costs.

When does tebipenem lose exclusivity?

No U.S. regulatory exclusivity period has started because the product has not been approved. Tebipenem therefore has no active FDA commercial exclusivity clock.

If approved, the product could potentially benefit from the Qualified Infectious Disease Product provisions of the Generating Antibiotic Incentives Now Act. QIDP designation can support an additional five years of exclusivity beyond otherwise available exclusivity periods, subject to statutory requirements and the product’s eligibility.[2] The designation does not itself create an approval or guarantee a ten-year period independent of other regulatory terms.

Patent protection and expiration timing

Spero’s public filings describe a patent estate covering tebipenem pivoxil hydrobromide, formulations, manufacturing processes, and therapeutic uses. The relevant patent terms extend into the 2030s, but the commercial value of the estate depends on:

  • Whether individual claims survive post-grant review or litigation.
  • Patent-term adjustment and any patent-term extension.
  • Whether the claims cover the approved commercial formulation.
  • Whether later-filed patents cover crystalline forms, manufacturing controls, or dosing regimens.
  • Whether a generic applicant can design around the asserted claims.

Because tebipenem is not approved, there is no current Orange Book patent listing and no active Paragraph IV litigation tied to an approved U.S. reference product. A precise loss-of-exclusivity date cannot be determined from the regulatory record alone.

Exclusivity category Current status
FDA approval exclusivity Not started
New chemical entity exclusivity Not available unless FDA determines eligibility at approval
QIDP exclusivity Designation granted; benefit would attach only after approval
Pediatric exclusivity Not established
Orange Book listing None
Patent protection Publicly disclosed patent estate extending into the 2030s
Generic Paragraph IV activity No public U.S. activity against an approved product

How large is the commercial opportunity for an oral carbapenem?

The commercial opportunity is concentrated in hospitalized or recently hospitalized patients with complicated urinary tract infections caused by resistant Gram-negative bacteria. These patients are often treated with intravenous carbapenems, such as ertapenem or meropenem, because oral options are limited when organisms produce ESBL enzymes or show resistance to fluoroquinolones and trimethoprim-sulfamethoxazole.

Tebipenem could create value in three settings:

  1. Earlier discharge for patients who otherwise require outpatient intravenous therapy.
  2. Avoidance of peripherally inserted central catheter placement and infusion services.
  3. Oral treatment for patients with resistant organisms when conventional oral agents are unsuitable.

The addressable market is narrower than the overall UTI market. Most uncomplicated UTIs do not require a carbapenem, and antimicrobial stewardship programs would likely restrict tebipenem to resistant infections or patients with a strong clinical need for oral therapy.

Competitive positioning

Treatment Route Primary strength Limitation relative to tebipenem
Ertapenem Intravenous or intramuscular Established ESBL coverage and once-daily dosing Requires parenteral administration
Meropenem Intravenous Broad Gram-negative and severe-infection coverage Hospital or infusion-based treatment
Fluoroquinolones Oral or intravenous Oral convenience and broad penetration Resistance and safety restrictions
Trimethoprim-sulfamethoxazole Oral Low-cost oral option Susceptibility and toxicity limitations
Fosfomycin Oral Activity against selected resistant urinary pathogens Limited use in complicated infections
Tebipenem Oral Potential oral carbapenem activity Unapproved, costly development, resistance concerns

The strongest economic argument is not replacement of all carbapenem use. It is replacement of some days of intravenous ertapenem or other parenteral therapy.

How strong is the tebipenem patent estate?

The patent estate is strategically valuable but commercially untested. Its strength depends less on the existence of patents than on claim scope around the final approved product.

Composition and salt protection

Patents covering tebipenem pivoxil hydrobromide or specific solid-state forms can be important because the hydrobromide salt is the proposed U.S. drug substance. Salt and polymorph claims may create barriers to direct substitution if they cover the form used in the approved product.

Formulation protection

The formulation is central to oral carbapenem development. Tebipenem pivoxil has stability, absorption, and manufacturing requirements that may require proprietary excipients, coatings, or controlled processing. Formulation patents could extend practical protection beyond an earlier compound patent if they cover the marketed dosage form.

Method-of-use protection

Method-of-use claims may cover treatment of complicated urinary tract infections, acute pyelonephritis, or infections caused by resistant Enterobacterales. Their value is reduced if a generic can obtain approval for a noninfringing indication or rely on a section viii statement excluding patented uses.

Manufacturing and process protection

Manufacturing patents may cover preparation of the active ingredient, conversion to the hydrobromide salt, impurity control, or production of a specific polymorph. These patents can raise technical barriers, but process patents are often harder to enforce than composition claims because the relevant manufacturing steps occur outside public view.

Overall, the estate appears stronger as a layered formulation, process, and use portfolio than as a single compound patent. The absence of an approved reference product prevents current measurement through Orange Book listings or Paragraph IV litigation outcomes.

Which companies are challenging tebipenem?

No public U.S. generic company has launched a Paragraph IV challenge to tebipenem pivoxil hydrobromide. The reason is structural: a Paragraph IV filing generally follows an approved drug with Orange Book-listed patents. Tebipenem has neither.

The principal competitive threats are therefore commercial and technical rather than litigation-based:

  • Generic ertapenem and other low-cost parenteral carbapenems.
  • Oral fluoroquinolones and trimethoprim-sulfamethoxazole where susceptibility permits.
  • New antibiotics targeting resistant Gram-negative infections.
  • Hospital stewardship policies that restrict oral carbapenem use.
  • Future generic entry after approval and Orange Book listing.

A generic launch scenario would likely begin only after approval, patent listing, and an ANDA filing. The timing would depend on patent expiry, any QIDP exclusivity, patent-term extension, litigation settlement, and the scope of formulation claims.

What licensing deals affect tebipenem’s financial trajectory?

Spero licensed tebipenem pivoxil hydrobromide from Meiji Seika Pharma in 2016. The transaction gave Spero development and commercialization rights outside specified retained territories and transferred a substantial portion of the asset’s future value to a company with greater U.S. development capability.[3]

Spero later entered an exclusive license agreement with GSK covering tebipenem. Publicly disclosed economics included:

Deal component Disclosed amount or structure
Upfront payment Approximately $66 million
Development and regulatory milestones Up to approximately $525 million
Commercial milestones Included in the overall milestone opportunity
Royalties Tiered royalties on commercial sales
Strategic effect Reduced Spero’s direct funding burden and transferred late-stage development risk

The agreement demonstrated that tebipenem had strategic value as a potential oral option for resistant urinary infections. The 2022 FDA rejection weakened the asset’s near-term economics and increased dependence on partner decisions, manufacturing remediation, and regulatory timing. Subsequent company disclosures indicated changes in the partnership and development strategy, with Spero retaining a central role in the asset’s future.

What is the financial trajectory for tebipenem?

Tebipenem has generated no U.S. product sales because it is not approved. Its financial trajectory has passed through three phases.

Phase one: licensing and clinical investment

Spero spent capital on U.S. development, including pharmacokinetic studies, manufacturing work, and the ADAPT-PO Phase 3 trial. The program’s value increased when it received QIDP, Fast Track, and priority review designations.

Phase two: partnering monetization

The GSK transaction created near-term financial support through the upfront payment and potential milestones. For Spero, this reduced the need to fund the entire program independently. For GSK, the agreement offered access to a potentially differentiated antibiotic without acquiring the full development company.

Phase three: regulatory remediation

The Complete Response Letter changed the expected cash-flow curve. Milestone payments tied to approval and commercialization became delayed or uncertain. Development expenses continued, while the product generated no recurring revenue.

A successful resubmission could produce a high-value, focused launch rather than a mass-market antibiotic launch. Likely revenue drivers would include:

  • Premium pricing relative to generic ertapenem.
  • Hospital formulary access.
  • Use in step-down therapy.
  • Infectious-disease specialist adoption.
  • Health-economic evidence showing savings from avoided infusion care.
  • Coverage by Medicare, Medicaid, and commercial plans.

The main financial risks are manufacturing costs, restricted stewardship use, payer resistance, and the possibility that physicians continue using inexpensive generic parenteral therapy.

What generic launch risks exist for tebipenem?

The risk of immediate generic competition is currently zero because there is no approved U.S. product. The risk increases sharply after approval.

Early post-approval risk

An ANDA applicant could challenge listed patents through Paragraph IV certification. If the reference sponsor sues within the statutory period, FDA approval may be stayed for up to 30 months, subject to litigation developments.

Mid-term risk

If composition claims expire earlier than formulation or process claims, generics may seek approval using a different formulation or manufacturing route. The practical barrier will depend on whether the approved product’s clinical performance is linked to protected formulation characteristics.

Long-term risk

Once patent and regulatory exclusivity expire, tebipenem could face rapid price erosion. Antibiotics generally have limited treatment duration, making annual patient revenue dependent on volume, institutional access, and pricing discipline.

What patent litigation and settlements affect tebipenem?

There is no public Orange Book patent litigation or Paragraph IV settlement affecting an approved U.S. tebipenem product. The current legal exposure is precommercial:

  • Patent validity and enforceability remain untested in U.S. litigation.
  • The scope of formulation and process claims has not been tested against an ANDA.
  • No launch-date settlement has been publicly established.
  • No biosimilar pathway applies because tebipenem is a small-molecule antibiotic, not a biologic.

The first major legal event would likely occur after a successful NDA resubmission and Orange Book listing.

How does tebipenem compare with other antibiotic assets?

Tebipenem has a different commercial profile from hospital-focused antibiotics such as cefiderocol, meropenem-vaborbactam, and ceftazidime-avibactam. Those products target severe resistant infections and are administered intravenously. Tebipenem’s potential value is in oral step-down treatment and avoidance of infusion infrastructure.

Its advantage is convenience. Its weakness is that convenience alone may not justify a high price if generic intravenous carbapenems remain available and hospitals restrict use to preserve carbapenem activity.

Key Takeaways

  • Tebipenem pivoxil hydrobromide is an investigational oral carbapenem for complicated urinary tract infections and acute pyelonephritis.
  • The FDA issued a Complete Response Letter in November 2022, primarily concerning manufacturing and CMC deficiencies.
  • The product has no FDA approval, U.S. sales, Orange Book listing, or active Paragraph IV litigation.
  • The commercial opportunity is concentrated in resistant urinary infections and oral step-down therapy.
  • Spero’s GSK licensing transaction included approximately $66 million upfront and up to approximately $525 million in potential milestones.
  • Patent protection is expected to extend into the 2030s through composition, formulation, process, and method-of-use claims, but claim strength has not been tested in litigation.
  • The central value driver is regulatory remediation, not clinical differentiation alone.
  • Generic competition is not an immediate risk but would become material after approval and expiration of applicable patents and exclusivity.
  • Revenue potential depends on hospital stewardship, payer coverage, pricing relative to generic ertapenem, and evidence of reduced infusion-related costs.

FAQs

Is tebipenem pivoxil hydrobromide available in the United States?

No. Tebipenem pivoxil hydrobromide is not FDA-approved and is not commercially available as a U.S. prescription product.

Is tebipenem a biologic or a generic drug?

No. Tebipenem is a small-molecule antibiotic. It is being developed through the FDA New Drug Application pathway, not the biosimilar pathway.

Does tebipenem have QIDP exclusivity?

The product received QIDP designation. QIDP-related exclusivity would become relevant only if the product receives FDA approval and satisfies the applicable statutory conditions.

What drug is the closest commercial comparator to tebipenem?

Generic ertapenem is the closest comparator because it is commonly used for ESBL-associated complicated urinary tract infections and offers once-daily parenteral dosing. Tebipenem’s proposed advantage is oral administration.

Can a generic company file a Paragraph IV challenge today?

There is no approved U.S. tebipenem reference product with Orange Book-listed patents, so there is currently no conventional Paragraph IV challenge pathway against a marketed U.S. tebipenem product.

References

  1. U.S. Food and Drug Administration. (2022). Complete response letter for tebipenem pivoxil hydrobromide NDA 215866.
  2. U.S. Congress. (2012). Food and Drug Administration Safety and Innovation Act, Title VIII: Generating Antibiotic Incentives Now Act.
  3. Spero Therapeutics, Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, Form 10-K.
  4. Spero Therapeutics, Inc. (2022). Spero Therapeutics and GSK enter into exclusive license agreement for tebipenem pivoxil hydrobromide.
  5. Spero Therapeutics, Inc. (2021). Tebipenem pivoxil hydrobromide Phase 3 ADAPT-PO study results and U.S. NDA submission materials.
  6. U.S. Food and Drug Administration. (2021). FDA grants priority review to tebipenem pivoxil hydrobromide NDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.